Literature DB >> 10683715

Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations.

A Marzo1, L Dal Bo, F Verga, N Ceppi Monti, G Abbondati, R A Tettamanti, F Crivelli, M R Uhr, S Ismaili.   

Abstract

This paper reports the results of a pharmacokinetic study involving 24 healthy volunteers and designed to characterise the rate and extent of diclofenac absorption after the administration of a single dose of diclofenac (CAS 15307-86-5) potassium salt 50 mg in sachet (Voltfast) and tablet (Cataflam) formulations. Timed plasma concentrations of diclofenac during a 12-h-period after dosing were measured by means of HPLC with UV detection at 275 nm and a quantification limit of 10 ng/ml; the method was fully validated for pharmacokinetic purposes. These plasma concentrations were used to calculate Cmax, tmax, trapezoidal AUC0-t and AUC0-infinity and t1/2 by means of noncompartmental analysis. Cmax and tmax are the parameters expressing the rate of absorption, whereas the AUCs reflect the extent of absorption. The rate of absorption with the sachets proved to be very fast, reaching peak values at 10 min in seven subjects and at 15 min in the remaining subjects: mean time was 13.68 min, with concentrations at 5 min being 38% of Cmax. The average time to peak concentration with the tablets was 53.10 min. The extent of absorption of the sachets and tablets was similar, with AUC0-infinity values of respectively 1362 and 1214 ng.ml-1.h, and a 90% confidence interval 1.05-1.20. The highly soluble potassium salt of diclofenac was rapidly absorbed, especially in its sachet formulation, and thus appears to be an invaluable analgesic agent that is particularly useful for quick pain relief.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683715     DOI: 10.1055/s-0031-1300162

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

Review 1.  Diclofenac potassium for oral solution (CAMBIA®) in the acute management of a migraine attack: clinical evidence and practical experience.

Authors:  Shivang Joshi; Alan M Rapoport
Journal:  Ther Adv Neurol Disord       Date:  2017-02-08       Impact factor: 6.570

2.  Bioavailability of diclofenac potassium at low doses.

Authors:  Burkhard Hinz; Julia Chevts; Bertold Renner; Henrike Wuttke; Thomas Rau; Andreas Schmidt; Istvan Szelenyi; Kay Brune; Ulrike Werner
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

Review 3.  Diclofenac potassium powder for oral solution: a review of its use in patients with acute migraine.

Authors:  Karly P Garnock-Jones
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

Review 4.  Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology.

Authors:  Roy Altman; Bill Bosch; Kay Brune; Paola Patrignani; Clarence Young
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

5.  Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy.

Authors:  Richard B Lipton; Pete Schmidt; Hans-Christoph Diener
Journal:  Headache       Date:  2017-04-06       Impact factor: 5.887

6.  Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain.

Authors:  Tigran Makunts; Isaac V Cohen; Kelly C Lee; Ruben Abagyan
Journal:  PLoS One       Date:  2018-04-18       Impact factor: 3.240

7.  On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state.

Authors:  Patrick J O'Dwyer; Karl J Box; Georgios Imanidis; Maria Vertzoni; Christos Reppas
Journal:  Eur J Pharm Sci       Date:  2021-10-07       Impact factor: 4.384

8.  Identifying and Characterizing Stress Pathways of Concern for Consumer Safety in Next-Generation Risk Assessment.

Authors:  Sarah Hatherell; Maria T Baltazar; Joe Reynolds; Paul L Carmichael; Matthew Dent; Hequn Li; Stephanie Ryder; Andrew White; Paul Walker; Alistair M Middleton
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.